东阳光长江药业是一家专注于抗病毒、内分泌及代谢性疾病、心血管疾病等治疗领域产品开发、生产及销售的中国制药企。主要产品包括抗流感药可威（磷酸奥司他韦胶囊和颗粒）等。从企业销售情况看，2023年共有27家企业在样本终端市场销售奥司他韦制剂。其中，宜昌东阳光长江药业以65.01%的销售额占比位居第一。Dongyangguang Changjiang Pharmaceutical (01558) rose more than 6%. As of press release, it was up 6.54% to HK$9.94, with a turnover of HK$21.0847 million.
The Zhitong Finance App learned that Dongyang Changjiang Pharmaceutical (01558) rose by more than 6%. As of press release, it had risen 6.54% to HK$9.94, with a turnover of HK$21.0847 million.
According to the news, according to the latest data from the Chinese Center for Disease Control and Prevention, the positive rate of the influenza virus continues to rise; more than 99% of it is influenza A. According to data from Dingdang Express, in the past month, the sales growth rate of the anti-influenza drugs oseltamivir and Sufida reached 164%.
Dongyangguang Changjiang Pharmaceutical is a Chinese pharmaceutical company focusing on the development, production and sale of products in the treatment fields of antiviral, endocrine and metabolic diseases, and cardiovascular diseases. The main products include the anti-influenza drug Covir (oseltamivir phosphate capsules and granules), etc. Judging from the company's sales situation, a total of 27 companies will sell oseltamivir preparations in the sample terminal market in 2023. Among them, Yichang Dongyangguang Changjiang Pharmaceutical ranked first with 65.01% sales.
